Avidity Biosciences, Inc.
RNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 14.65 | 0.24 | -0.39 | -0.21 |
| FCF Yield | -9.49% | -18.66% | -12.02% | -10.01% |
| EV / EBITDA | -8.06 | -2.08 | -4.66 | -5.76 |
| Quality | ||||
| ROIC | -25.78% | -42.72% | -29.47% | -29.25% |
| Gross Margin | 100.00% | 78.02% | 84.96% | 93.15% |
| Cash Conversion Ratio | 0.93 | 0.56 | 0.78 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.71% | 0.83% | 10.77% | 59.02% |
| Free Cash Flow Growth | -149.76% | 11.36% | -41.13% | -157.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.57 | 0.75 | 1.86 | 2.63 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.71 |
| Cash Conversion Cycle | -167.18 | -1,488.17 | -1,126.72 | -2,081.66 |